ZURA trades 1972.3% below Wall Street's consensus target of $20.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes ZURA achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 8 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 19, 2026, Zura Bio Limited (ZURA) has a Wall Street consensus price target of $20.00, based on estimates from 8 covering analysts. With the stock currently trading at $0.97, this represents a potential upside of +1972.3%. The company has a market capitalization of $92M.
Analyst price targets range from a low of $20.00 to a high of $20.00, representing a 0% spread in expectations. The median target of $20.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 7 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, ZURA trades at a trailing P/E of -1.3x. Analysts expect EPS to grow -13.3% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
IMVTImmunovant, Inc. | $6.8B | $33.17 | $40.00 | +20.6% | Buy | — | 23 |
ARQTArcutis Biotherapeutics, Inc. | $3.5B | $27.61 | $41.80 | +51.4% | Buy | 66.9x | 12 |
KYMRKymera Therapeutics, Inc. | $10.0B | $121.13 | $141.53 | +16.8% | Buy | — | 27 |
PRAXPraxis Precision Medicines, Inc. | $8.5B | $305.19 | $611.69 | +100.4% | Buy | — | 18 |
ABBVAbbVie Inc. | $505.3B | $286.01 | $308.88 | +8.0% | Buy | 20.5x | 44 |
LLYEli Lilly and Company | $1.3T | $1382.54 | $1445.12 | +4.5% | Buy | 39.1x | 46 |
REGNRegeneron Pharmaceuticals, Inc. | $97.4B | $945.53 | $904.60 | -4.3% | Buy | 13.9x | 49 |
INVAInnoviva, Inc. | $1.4B | $18.40 | $38.00 | +106.5% | Buy | 7.6x | 11 |
CABACabaletta Bio, Inc. | $173M | $1.06 | $16.33 | +1447.9% | Buy | — | 12 |
CRLCharles River Laboratories International, Inc. | $16.1B | $333.25 | $308.36 | -7.5% | Buy | 29.3x | 37 |
Quick answers to the most common questions about buying ZURA stock.
The consensus Wall Street price target for ZURA is $20, representing 1972.3% upside from the current price of $0.9651. With 8 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
ZURA has a consensus rating of "Buy" based on 8 Wall Street analysts. The rating breakdown is predominantly bullish, with 7 Buy/Strong Buy ratings. The consensus 12-month price target of $20 implies 1972.3% upside from current levels.
ZURA's current price is $0.9651 with a consensus target of $20 (1972.3% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $20 for ZURA, while the most conservative target is $20. The consensus of $20 represents the median expectation. These targets typically reflect 12-month expectations.
ZURA is moderately covered, with 8 analysts providing price targets and ratings. Of these, 1 have Strong Buy ratings, 6 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ZURA stock forecast based on 8 Wall Street analysts shows a consensus price target of $20, with estimates ranging from $20 (bear case) to $20 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on ZURA, with a "Buy" consensus rating and $20 price target (1972.3% upside). 7 of 8 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ZURA analyst price targets range from $20 to $20, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $20 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.